Last quarter (Q4 2023), Altimmune's total revenue was $37.00K, a decrease of -133.64% from the same quarter last year. In Q4, Altimmune's net income was $-31.64M. See Altimmune’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 426.00K	$ 426.00K	$ -68.00K	$ 4.41M	$ 8.19M	$ 5.80M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 426.00K	$ 426.00K	$ -68.00K	$ 4.41M	-	-
Operating Expense	$ 96.36M	$ 96.36M	$ 87.67M	$ -101.32M	$ 62.98M	$ 26.27M
Operating Income	$ -95.93M	$ -95.93M	$ -87.74M	$ -85.54M	$ -54.80M	$ -20.46M
Net Non Operating Interest Income Expense	$ 7.32M	$ 7.32M	$ 2.86M	$ 197.09K	$ 313.09K	$ 841.16K
Other Income Expense	$ 12.25M	$ 12.25M	$ 32.00K	$ 11.77M	$ 24.15K	$ -954.86K
Pretax Income	$ -88.45M	$ -88.45M	$ -84.91M	$ -97.09M	$ -54.46M	$ -20.58M
Tax Provision	-	-	$ -197.00K	-	$ -5.42M	$ -58.50K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -88.45M	$ -88.45M	$ -84.71M	$ -97.12M	$ -49.04M	$ -20.97M
Basic EPS	$ -1.65	$ -1.66	$ -1.81	$ -2.35	$ -1.91	$ -1.60
Diluted EPS	$ -1.64	$ -1.66	$ -1.81	$ -2.35	$ -1.91	$ -1.60
Basic Average Shares	$ 212.99M	$ 53.25M	$ 46.93M	$ 41.28M	$ 25.64M	$ 13.12M
Diluted Average Shares	$ 212.99M	$ 53.25M	$ 46.93M	$ 41.28M	$ 25.64M	$ 13.12M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 96.36M	$ 96.36M	$ -87.67M	$ -101.32M	$ 62.98M	$ 26.27M
Net Income From Continuing And Discontinued Operation	$ -88.45M	$ -88.45M	$ -84.71M	$ -97.12M	$ -49.04M	$ -20.52M
Normalized Income	$ -41.60M	$ -57.45M	-	-	$ -49.04M	$ -19.55M
Interest Expense	-	-	-	-	$ 9.42K	$ 2.24K
EBIT	$ -88.41M	$ -88.41M	$ -84.90M	$ -97.09M	$ -54.45M	$ -20.58M
EBITDA	$ -90.38M	$ -90.38M	$ -84.90M	$ -96.53M	$ -54.02M	$ -20.19M

Currency in USD

Altimmune Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing